Esophageal Varices Treatment & Management
- Author: Samy A Azer, MD, PhD, MPH; Chief Editor: Julian Katz, MD more...
Medical Care
- Esophageal varices with no history of bleeding
- Patients with esophageal varices and no previous history of variceal hemorrhage should be treated with nonselective beta-adrenergic blockers (eg, propranolol, nadolol, timolol), provided that the use of beta-blockers is not contraindicated (eg, because of insulin-dependent diabetes mellitus, severe chronic obstructive lung disease, congestive heart failure).[1, 5, 6, 7, 8]
- The dose of nonselective beta-blockers is determined by a 25% decrease in resting heart rate or a decrease in heart rate to 55 beats per minute or the development of adverse effects.
- The use of beta-blockers decreases the risk of initial variceal bleeding by approximately 45%.
- If contraindications to using beta-blockers exist, long-acting nitrates (eg, isosorbide 5-mononitrate) are alternatives.
- Treatment with beta-blockers should be continued indefinitely.
- The role of endoscopic sclerotherapy or variceal ligation for prevention of esophageal variceal hemorrhage is as effective as treatment with propranolol in decreasing the incidence of first variceal bleeding and death in cirrhotic patients with higher-risks of bleeding from esophageal varices.
- Kumar et al investigated whether endoscopic variceal ligation alone or a combination of endoscopic variceal ligation plus propranolol and isosorbide mononitrate was more effective for secondary prophylaxis in patients with previous variceal bleeding.[9] Patients were randomly assigned to receive endoscopic variceal ligation alone (n = 89) or the combination therapy (n = 88). No difference between the groups was observed for rebleeding 2 years after initial therapy (P = 0.822).[9] The authors concluded that endoscopic variceal ligation alone is sufficient to prevent variceal rebleeding, whereas addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation may increase risk for adverse effects.
- Combined sclerotherapy and treatment with nonselective beta-blockers offer no advantages over the use of beta-blockers alone for prevention of esophageal varices hemorrhage.
- Approximately 50% of patients with NASH with severe fibrosis had esophageal varices. NASH patients with esophagogastric varices need to be followed up carefully like patients with other chronic liver disorders.
- Bleeding esophageal varices
- Assess the rate and volume of bleeding. Check blood pressure and pulse with the patient in the supine position and with the patient in a sitting position.
- Gain venous access and obtain blood for immediate hematocrit measurement. Obtain a type and cross-match. Measure the platelet count and prothrombin time. Send blood for renal and liver function tests and measure serum electrolytes.
- Provide emergency treatment as outlined below.
- Emergency treatment
- Promptly resuscitate and restore the circulating blood volume of patients with suspected cirrhosis and variceal hemorrhage.
- Establish intravenous access for blood transfusion. While the blood is being cross-matched, start rapid infusion of 5% dextrose and colloid solution until the blood pressure is restored and urine output is adequate.
- Establish airway protection in patients with massive upper GI tract bleeding, especially if the patient is not fully conscious.
- If indicated, correct clotting factor deficiencies with fresh frozen plasma, fresh blood, and vitamin K-1.
- Insert a nasogastric tube to assess the severity of the bleeding and to lavage gastric contents before performing endoscopy.
- Consider pharmacologic therapy (octreotide or somatostatin) and endoscopy as soon as the patient has been resuscitated. The aim is to establish the cause of and to control the bleeding.
- Endoscopic therapy probably has replaced balloon tamponade as the initial therapy for variceal bleeding. Balloon tamponade is now rarely necessary, and, when it is used, it must be performed by experienced personnel because the procedure is potentially dangerous.
- D'Amico et al reviewed studies that compared emergency sclerotherapy to vasoconstrictive drugs for variceal bleeding in patients with cirrhosis and concluded that vasoactive drugs are safe and effective whenever endoscopic ligation (banding) therapy is not promptly available.[10] In addition, the pharmacotherapy seemed to create less adverse events than emergency sclerotherapy. The meta-analysis included 17 trials representing 1817 patients. Vasoactive drugs varied between trials (ie, vasopressin, 1 trial; terlipressin, 1 trial; somatostatin, 5 trials; octreotide 10 trials). No significant differences were found comparing sclerotherapy with each vasoactive drug for any outcome regarding efficacy; however, adverse events were significantly more frequent with sclerotherapy.[10]
- Endoscopic sclerotherapy
- Endoscopic sclerotherapy is successful in controlling acute esophageal variceal bleeding in up to 90% of patients. Hemorrhagic control should be obtained with 1-2 sessions. Patients continuing to bleed after 2 sessions should be considered for alternative methods to control their bleeding.
- In the United States, sodium tetradecyl sulfate or sodium morrhuate has generally been used as a sclerosant, whereas polidocanol or ethanolamine has been more popular in Europe. Variations in the technique or the sclerosant used have not been shown to influence the outcome.
- Serious complications related to sclerotherapy have been reported in 15-20% of patients, with an associated mortality rate of 2%.
- Complications of sclerotherapy may include mucosal ulceration, bleeding, esophageal perforation, mediastinitis, and pulmonary complications. Long-term complications, such as esophageal stricture formation, may also occur.
- Endoscopic variceal ligation (banding)[11, 12]
- Endoscopic variceal ligation is based on the widely used technique of rubber-band ligation of hemorrhoids. The esophageal mucosa and the submucosa containing varices are ensnared, causing subsequent strangulation, sloughing, and eventual fibrosis, resulting in obliteration of the varices.
- Rebleeding occurs less frequently with endoscopic variceal ligation (26%) than with endoscopic sclerotherapy (45%).
- Endoscopic ligation requires placement of an opaque cylinder over the end of the endoscope. This decreases the endoscopic field of view and may allow pooling of blood. Thus, in patients with active bleeding, visualization may be impaired more with ligation than with sclerotherapy.
- Clinical trials have demonstrated that ligation and sclerotherapy achieved similar rates of initial hemostasis in patients whose varices were actively bleeding at the time of treatment.
- Local complications are less common with ligation compared with sclerotherapy. For example, esophageal strictures were found to be less common with ligation compared with sclerotherapy. Systemic complications, such as pulmonary infections and bacterial peritonitis, were not significantly different between the 2 groups. However, a trend was observed toward a decrease in these 2 complications in patients treated with ligation.
Surgical Care
Surgical care and therapeutic radiologic procedures for variceal hemorrhage
Approximately 5-10% of patients with esophageal variceal hemorrhage have conditions that cannot be controlled by endoscopic and/or pharmacologic treatment. Balloon tamponade (eg, Minnesota tube, Sengstaken-Blakemore tube, Linton-Nachlas tube) may be used as a temporary option in the management of these patients. Definitive salvage options may include the following:
- Surgical interventions include the following:
- Portosystemic shunt
- Devascularization (transabdominal devascularization of the lower 5 cm of the esophagus and the upper two thirds of the stomach, with staple gun transection of the lower esophagus) is rarely performed but may have a role in patients with portal and splenic vein thrombosis who are not suitable candidates for shunt procedures and who continue to have variceal bleeding despite endoscopic and pharmacologic treatment.
- Orthotopic liver transplantation is the treatment of choice in patients with advanced liver disease.
- Therapeutic radiologic procedures include the following:
- Percutaneous transhepatic embolization (PTE) of gastroesophageal varices involves catheterization of the gastric collaterals that supply blood to varices via the transhepatic route. A variety of agents had been used, with varying degrees of success in controlling acute bleeding. Generally, PTE is less effective than endoscopic sclerotherapy for treatment of variceal hemorrhage, and it is much less effective compared with medical and surgical options. Thus, it should be reserved for situations in which acute variceal bleeding is not controlled by pharmaceutical treatment, endoscopic sclerotherapy, or endoscopic variceal ligation and in which contraindications for surgical management are present.
- Transjugular intrahepatic portosystemic shunt (TIPS) placement is an effective salvage procedure for stopping acute variceal hemorrhage after failure of medical and endoscopic treatment. However, this procedure is associated with a number of complications; 20% of patients develop encephalopathy, and 50% may occlude their shunt within 1 year. Thus, TIPS placement should be considered as a bridge to subsequent liver transplantation.
Role of liver transplantation
Liver transplantation is indicated for patients with end-stage liver disease resulting in cirrhosis (viral hepatitis, alcoholic, nonalcoholic steatohepatitis, cholestatic liver disease), fulminate liver failure, and early stage hepatocellular carcinoma. Careful assessment of patients for liver transplantation is required. However, this procedure has revolutionalized the management of patients with end-stage liver disorders.
Consultations
Consider early consultation with a gastroenterologist and a surgeon, particularly for patients with active bleeding from esophageal varices.
Diet
In patients with hemodynamically significant upper GI tract bleeding, a nasogastric tube should be in place for 24 hours to assist in identifying any rebleeding. Gastric lavage may be performed frequently through the nasogastric tube, and the volume and appearance of material aspirated from the stomach should be recorded. Do not allow any food by mouth.
Lubel JS, Angus PW. Modern management of portal hypertension. Intern Med J. Jan 2005;35(1):45-9. [Medline]. [Full Text].
Obara K. Hemodynamic mechanism of esophageal varices. Dig Endosc. Jan 2006;18(1):6-9.
Ravindra KV, Eng M, Marvin M. Current management of sinusoidal portal hypertension. Am Surg. Jan 2008;74(1):4-10. [Medline].
Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology. Oct 1998;28(4):926-31. [Medline]. [Full Text].
D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19(4):475-505. [Medline].
Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol. 2003;38 suppl 1:S54-68. [Medline].
Samonakis DN, Triantos CK, Thalheimer U, Patch DW, Burroughs AK. Management of portal hypertension. Postgrad Med J. Nov 2004;80(949):634-41. [Medline]. [Full Text].
Chang YW. Indication of treatment for esophageal varices: who and when?. Dig Endosc. Jan 2006;18(1):10-5.
[Best Evidence] Kumar A, Jha SK, Sharma P, et al. Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence. Gastroenterology. Sep 2009;137(3):892-901, 901.e1. [Medline].
[Best Evidence] D'Amico G, Pagliaro L, Pietrosi G, Tarantino I. Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patients. Cochrane Database Syst Rev. Mar 17 2010;3:CD002233. [Medline].
Lay CS, Tsai YT, Lee FY, et al. Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis. J Gastroenterol Hepatol. Feb 2006;21(2):413-9. [Medline].
[Best Evidence] Gluud LL, Klingenberg S, Nikolova D, Gluud C. Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials. Am J Gastroenterol. Dec 2007;102(12):2842-8; quiz 2841, 2849. [Medline].
Arguedas MR, Heudebert GR, Eloubeidi MA, Abrams GA, Fallon MB. Cost-effectiveness of screening, surveillance, and primary prophylaxis strategies for esophageal varices. Am J Gastroenterol. Sep 2002;97(9):2441-52. [Medline].
Garcia-Tsao G. Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: a caution. Gastroenterology. Sep 1999;117(3):740-2. [Medline].
Garcia-Tsao G. Portal hypertension. Curr Opin Gastroenterol. May 2000;16(3):282-9. [Medline].
Garcia-Tsao G, Sanyal AJ, Grace ND, Carey WD. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol. Sep 2007;102(9):2086-102. [Medline].
Goulis J, Patch D, Burroughs AK. Bacterial infection in the pathogenesis of variceal bleeding. Lancet. Jan 9 1999;353(9147):139-42. [Medline].
[Best Evidence] Groszmann RJ, Garcia-Tsao G, Bosch J, et al, for the Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. Nov 24 2005;353(21):2254-61. [Medline]. [Full Text].
Nakamura S, Konishi H, Kishino M, et al. Prevalence of esophagogastric varices in patients with non-alcoholic steatohepatitis. Hepatol Res. Jun 2008;38(6):572-9. [Medline].
Nevens F. Review article: a critical comparison of drug therapies in currently used therapeutic strategies for variceal haemorrhage. Aliment Pharmacol Ther. Sep 2004;20 Suppl 3:18-22; discussion 23. [Medline].
Patch D, Armonis A, Sabin C, et al. Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding. Gut. Feb 1999;44(2):264-9. [Medline]. [Full Text].
Poo JL, Jimenez W, Maria Munoz R, et al. Chronic blockade of endothelin receptors in cirrhotic rats: hepatic and hemodynamic effects. Gastroenterology. Jan 1999;116(1):161-7. [Medline].

